BRISTOL MYERS SQUIBB CO (BMY)
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
📈 **POSITIVE** • Medium confidence analysis (77%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business